Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Incyte will acquire Villaris and the exclusive global rights to develop and commercialize auremolimab (VM6, an anti-IL-15Rβ monoclonal antibody) for all uses, including in vitiligo and other autoimmune and inflammatory diseases.
Lead Product(s): Auremolimab
Therapeutic Area: Dermatology Product Name: VM6
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Incyte Corporation
Deal Size: $1,430.0 million Upfront Cash: $70.0 million
Deal Type: Acquisition October 03, 2022